FRAMINGHAM, Mass.--(BUSINESS WIRE)--Boston Heart Diagnostics is pleased to announce the appointment of Pat Noland as President effective April 2017. Pat brings a wealth of leadership experience in laboratory sciences, and he has proven success in developing and executing strategies for revenue and earnings growth as well as in leadership, communication, and organizational development. For the past 25 years, Pat has worked for various companies such as Laboratory Corporation of America (LabCorp), StrataDx- Strata Pathology Services Inc., and Genetic Signatures Limited, in a number of leadership roles.
“With Pat’s vast experience in laboratory services and his history of driving growth and innovation, he is the perfect fit for Boston Heart Diagnostics,” said Bob Gorman, Senior Vice President, Clinical Diagnostics, US-East Eurofins.
Pat has most recently been working as a US Market Consultant at Genetic Signatures Limited since July 2016— previously serving as Executive Vice President of US Operations.
Prior to his time at Genetic Signatures Limited, he served as Chief Executive Officer of Strata Pathology Services, Inc. where he repositioned the company to focus on institutional and dermatology markets.
He had a 17-year tenure at the $9.7 billion clinical laboratory company, LabCorp, where he served as Senior Vice President, responsible for developing and implementing a new partnerships-focused hospital strategy, designed to expand the available US market. Previously, he held full P&L responsibility for DIANON Systems, LabCorp’s premium anatomic pathology brand, as well as a series of other senior leadership roles in strategic assignments. Pat began his LabCorp career in field sales and sales management in the Atlanta, Georgia market.
He holds a master’s degree in Business Administration from Kennasaw State University in Georgia, and a bachelor’s of science degree in Advertising from the University of Georgia in Athens.
“I am excited to join the team at Boston Heart and help lead our ongoing commitment to improve the way providers and patients manage heart disease and risk,” said Pat Noland, President, Boston Heart Diagnostics. “Together, we can transform the treatment of cardiovascular disease through personalized diagnostics and lifestyle programs, and help patients on their journey in improving heart health.”
About Boston Heart
Boston Heart Diagnostics is transforming the treatment of cardiovascular disease by providing healthcare providers and their patients with novel, personalized diagnostics and integrated customized lifestyle programs that have the power to change the way clinicians and patients communicate about disease and improve heart health. Boston Heart looks beyond the “good” and “bad” cholesterol assessment that conventional labs provide to give a more complete picture of heart health. Founded by renowned cardiovascular researchers and led by seasoned lab and diagnostic executives, Boston Heart is one of the fastest growing health companies in the country. For more information on Boston Heart Diagnostics, please visit www.BostonHeartDiagnostics.com